Pyrimidines for degrading bruton's tyrosine kinase

The present invention provides for compounds of formula (I); wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.

Saved in:
Bibliographic Details
Main Authors RIVKIN, ALEXEY A, BIANNIC, BERENGER, MALI, VENKAT REDDY, ZHAO, XIAN-RUI, JIA, ZHAOZHONG J, ADAMS, ASHLEY M, ZABLOCKI, JEFFERY A, KATCHER, MATTHEW H, BIAN, ZHI-GUO, WOLLER, KEVIN R, PAYETTE, JOSHUA N, JIANG, XING-YU, BURKE, JASON P, MORTEZAEI, SHAHAB, MARIN, VIOLETA L, SCHOLZ, SPENCER O, NOEY, ELIZABETH L, OKANO, AKINORI
Format Patent
LanguageChinese
English
Published 01.12.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides for compounds of formula (I); wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.
Bibliography:Application Number: TW20230110487